Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety considerations for cereblon-recruiting targeted protein degraders.

Nature reviews. Drug discovery·2026
Same author

Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR Study.

JCO precision oncology·2023
Same author

Olaparib in Patients With Metastatic Prostate Cancer With <i>BRCA1</i>/<i>2</i> Mutation: Results From the TAPUR Study.

JCO precision oncology·2023
Same author

Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

JCO precision oncology·2022
Same author

Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With <i>ERBB2</i> Amplification or <i>ERBB2/3</i> Mutations: Results From the TAPUR Study.

JCO precision oncology·2022
Same author

RATEmiRs: the rat atlas of tissue-specific and enriched miRNAs for discerning baseline expression exclusivity of candidate biomarkers.

RNA biology·2020
Same journal

Comparison of Standard Clinical Pathology Parameter Values in Fasted and Fed Rats and Non-human Primates.

Toxicologic pathology·2026
Same journal

Time-Dependent Autolysis in Ex Vivo-Maintained Rat Tissue in Saline: A Descriptive Study and Practical Guidance for Histopathologic Assessment.

Toxicologic pathology·2026
Same journal

New Approach Methodologies (NAMs) for Carcinogenicity Evaluation.

Toxicologic pathology·2026
Same journal

2025 International Academy of Toxicologic Pathology (IATP) Satellite Symposium: Pathology Working Groups (PWGs) in Toxicologic Pathology.

Toxicologic pathology·2026
Same journal

Toxicologic Pathology Forum*: Opportunities and Challenges in the Use of Artificial Intelligence in Nonclinical Toxicologic Histopathology Evaluations.

Toxicologic pathology·2026
Same journal

New Modalities and Carcinogenicity Assessment.

Toxicologic pathology·2026
See all related articles

Related Experiment Video

Updated: May 25, 2026

Assessment of Chemical Toxicity in Adult Drosophila Melanogaster
07:02

Assessment of Chemical Toxicity in Adult Drosophila Melanogaster

Published on: March 24, 2023

Juvenile immunotoxicology.

Michael P Holsapple1, Raegan O'Lone

  • 1ILSI Health and Environmental Sciences Institute, Washington, DC 20005-1743, USA.

Toxicologic Pathology
|January 19, 2012
PubMed
Summary
This summary is machine-generated.

Developmental immunotoxicity (DIT) testing assesses risks from early-life exposure to immune-damaging substances. This review highlights juvenile exposure impacts and unique challenges in pharmaceutical DIT assessment.

More Related Videos

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants
07:08

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants

Published on: March 6, 2018

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
14:01

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Published on: July 22, 2011

Related Experiment Videos

Last Updated: May 25, 2026

Assessment of Chemical Toxicity in Adult Drosophila Melanogaster
07:02

Assessment of Chemical Toxicity in Adult Drosophila Melanogaster

Published on: March 24, 2023

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants
07:08

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants

Published on: March 6, 2018

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
14:01

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Published on: July 22, 2011

Area of Science:

  • Immunotoxicology
  • Developmental Biology
  • Pharmacology

Background:

  • Developmental immunotoxicity (DIT) concerns potential immune system damage from early-life exposure to toxicants.
  • Past research has emphasized addressing impacts across all developmental stages.
  • This article specifically focuses on the juvenile development stage and pharmaceutical DIT.

Purpose of the Study:

  • To review the current state of DIT science for pharmaceuticals.
  • To highlight the significance of the juvenile exposure window.
  • To discuss unique considerations for pharmaceutical DIT testing.

Main Methods:

  • Review of existing literature and workshop discussions.
  • Synthesis of expert opinions from pharmaceutical, biotechnology, academic, and regulatory sectors (FDA, EMA).
  • Focus on identifying key issues distinguishing pharmaceutical DIT.

Main Results:

  • No specific regulatory guidelines for DIT exist for drugs or chemicals.
  • General DIT assessment principles are found within broader toxicity guidelines.
  • The juvenile stage is a critical window for DIT assessment.

Conclusions:

  • Further development of DIT testing strategies is needed, particularly for pharmaceuticals.
  • Regulatory guidance for DIT assessment is currently lacking.
  • Addressing DIT across all developmental stages, with emphasis on the juvenile period, is crucial for drug safety.